Short Interest in Invuity, Inc. (IVTY) Decreases By 35.6%

Invuity, Inc. (NASDAQ:IVTY) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 499,038 shares, a decrease of 35.6% from the January 12th total of 775,369 shares. Currently, 3.9% of the company’s shares are sold short. Based on an average daily trading volume, of 295,751 shares, the short-interest ratio is currently 1.7 days.

Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Invuity during the 2nd quarter valued at about $101,000. OxFORD Asset Management LLP bought a new stake in shares of Invuity during the 2nd quarter valued at about $374,000. Wells Fargo & Company MN boosted its position in shares of Invuity by 987.0% during the 4th quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock valued at $398,000 after purchasing an additional 58,292 shares in the last quarter. CAPROCK Group Inc. boosted its position in shares of Invuity by 28.6% during the 3rd quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Invuity by 16.3% in the second quarter. Vanguard Group Inc. now owns 402,680 shares of the medical instruments supplier’s stock worth $2,919,000 after acquiring an additional 56,527 shares in the last quarter. Institutional investors own 68.09% of the company’s stock.

Shares of Invuity (IVTY) opened at $4.00 on Monday. Invuity has a 52-week low of $3.75 and a 52-week high of $9.70. The company has a debt-to-equity ratio of 5.39, a quick ratio of 2.47 and a current ratio of 2.90. The company has a market capitalization of $68.56, a PE ratio of -1.62 and a beta of -0.50.

Several equities research analysts have recently weighed in on IVTY shares. Zacks Investment Research cut Invuity from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies restated a “buy” rating and set a $12.00 target price on shares of Invuity in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $10.25.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Invuity, Inc. (IVTY) Decreases By 35.6%” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/12/short-interest-in-invuity-inc-ivty-decreases-by-35-6.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply